Drug Profile
F 12248
Latest Information Update: 15 Nov 2005
Price :
$50
*
At a glance
- Originator Pierre Fabre
- Class Antihyperlipidaemics
- Mechanism of Action Squalene monooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis
Most Recent Events
- 15 Nov 2005 No development reported - Preclinical for Atherosclerosis in France (unspecified route)
- 21 Nov 2002 bioMérieux - Pierre Fabre Group has demerged
- 16 May 2001 Pierre Fabre has merged with bioMérieux Alliance